Engineered cellular immunotherapies in cancer and beyond

Finck, Amanda; Blanchard, Tatiana; Roselle, Christopher P; Golinelli, Giulia; June, Carl H.

doi:10.1038/s41591-022-01765-8

Cited by 178 publications

(122 citation statements)

References 158 publications

Supporting

Mentioning

122

Contrasting

Order By: Relevance

“…Therapeutic cells such as CAR T cells and antigen-primed dendritic cells (DC) have been developed for targeting tumor-associated antigens. 90 Immunomodulatory drugs in the form of monoclonal/bispecific antibodies and small molecules have been used for redirecting or altering the phenotypes and functions of immunosuppressive cell types such as myeloid derived suppressor cells and regulatory T cells. 91 92 Treatment efficacy often depends on the efficient targeting and delivery of these specific leukocytes to the tumor microenvironment.…”

Section: Introductionmentioning

confidence: 99%

MRI techniques for immunotherapy monitoring

Lau

Corrie²,

Gallagher³

2022

J Immunother Cancer

View full text Add to dashboard Cite

MRI is a widely available clinical tool for cancer diagnosis and treatment monitoring. MRI provides excellent soft tissue imaging, using a wide range of contrast mechanisms, and can non-invasively detect tissue metabolites. These approaches can be used to distinguish cancer from normal tissues, to stratify tumor aggressiveness, and to identify changes within both the tumor and its microenvironment in response to therapy. In this review, the role of MRI in immunotherapy monitoring will be discussed and how it could be utilized in the future to address some of the unique clinical questions that arise from immunotherapy. For example, MRI could play a role in identifying pseudoprogression, mixed response, T cell infiltration, cell tracking, and some of the characteristic immune-related adverse events associated with these agents. The factors to be considered when developing MRI imaging biomarkers for immunotherapy will be reviewed. Finally, the advantages and limitations of each approach will be discussed, as well as the challenges for future clinical translation into routine clinical care. Given the increasing use of immunotherapy in a wide range of cancers and the ability of MRI to detect the microstructural and functional changes associated with successful response to immunotherapy, the technique has great potential for more widespread and routine use in the future for these applications.

show abstract

Section: Introductionmentioning

confidence: 99%

MRI techniques for immunotherapy monitoring

Lau

Corrie²,

Gallagher³

2022

J Immunother Cancer

View full text Add to dashboard Cite

show abstract

“…Compared with traditional chemotherapy ( Ihrig et al, 2020 ), immunotherapy ( Hegde and Chen, 2020 ) may induce a stronger sustained antitumor immune response in patients with advanced malignant tumors ( Yu et al, 2019 ; Zhang et al, 2020b ). Cancer immunotherapy is considered a treatment that aims to restore the immune system’s ability to recognize and reject cancer by removing tumor cells through the cancer–immune cycle ( Carlberg and Velleuer, 2022 ; Finck et al, 2022 ; Lang et al, 2022 ; Tian et al, 2022 ). When cancer cells die through apoptosis or necrosis, tumor cell surface antigens are captured by APCs (eg, dendritic cells) ( Zhang et al, 2022a ; Zhang et al, 2022b ).…”

Section: Mechanisms Of Cancer Immunotherapymentioning

confidence: 99%

Biomimetic nanoparticles for tumor immunotherapy

Chen

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Currently, tumor treatment research still focuses on the cancer cells themselves, but the fact that the immune system plays an important role in inhibiting tumor development cannot be ignored. The activation of the immune system depends on the difference between self and non-self. Unfortunately, cancer is characterized by genetic changes in the host cells that lead to uncontrolled cell proliferation and evade immune surveillance. Cancer immunotherapy aims to coordinate a patient’s immune system to target, fight, and destroy cancer cells without destroying the normal cells. Nevertheless, antitumor immunity driven by the autoimmune system alone may be inadequate for treatment. The development of drug delivery systems (DDS) based on nanoparticles can not only promote immunotherapy but also improve the immunosuppressive tumor microenvironment (ITM), which provides promising strategies for cancer treatment. However, conventional nano drug delivery systems (NDDS) are subject to several limitations in clinical transformation, such as immunogenicity and the potential toxicity risks of the carrier materials, premature drug leakage at off-target sites during circulation and drug load content. In order to address these limitations, this paper reviews the trends and progress of biomimetic NDDS and discusses the applications of each biomimetic system in tumor immunotherapy. Furthermore, we review the various combination immunotherapies based on biomimetic NDDS and key considerations for clinical transformation.

show abstract

“…Chimeric antigen receptor (CAR) T cells have become today the paradigm of immunotherapy, able to direct the patient’s own immune cells against target cancer antigens, through an engineered receptor structure [ 143 , 144 ]. CAR T cells have demonstrated exceptional results in trials and real-life experiences for non-Hodgkin lymphoma, multiple myeloma and B cell acute lymphoblastic leukemia even in refractory or heavily pretreated contexts, showing, in many cases, complete and durable responses [ 145 ]. This success in other lymphoproliferative disorders and hematologic malignancies has encouraged investigations in the context of R/R HL [ 146 ].…”

Section: Management Of Relapsed/refractory Hodgkin Lymphomamentioning

confidence: 99%

Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma

Leroyer

Ziegler

Moulin

et al. 2022

JCM

View full text Add to dashboard Cite

Despite years of clinical progress which made Hodgkin lymphoma (HL) one of the most curable malignancies with conventional chemotherapy, refractoriness and recurrence may still affect up to 20–30% of patients. The revolution brought by the advent of immunotherapy in all kinds of neoplastic disorders is more than evident in this disease because anti-CD30 antibodies and checkpoint inhibitors have been able to rescue patients previously remaining without therapeutic options. Autologous hematopoietic cell transplantation still represents a significant step in the treatment algorithm for chemosensitive HL; however, the possibility to induce complete responses after allogeneic transplant procedures in patients receiving reduced-intensity conditioning regimens informs on its sensitivity to immunological control. Furthermore, the investigational application of adoptive T cell transfer therapies paves the way for future indications in this setting. Here, we seek to provide a fresh and up-to-date overview of the new immunotherapeutic agents dominating the scene of relapsed/refractory HL. In this optic, we will also review all the potential molecular mechanisms of tumor resistance, theoretically responsible for treatment failures, and we will discuss the place of allogeneic stem cell transplantation in the era of novel therapies.

show abstract

Engineered cellular immunotherapies in cancer and beyond

Cited by 178 publications

References 158 publications

MRI techniques for immunotherapy monitoring

MRI techniques for immunotherapy monitoring

Biomimetic nanoparticles for tumor immunotherapy

Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma

Contact Info

Product

Resources

About